Compare NNVC & IPWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNVC | IPWR |
|---|---|---|
| Founded | 2005 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.7M | 33.9M |
| IPO Year | 2008 | 2013 |
| Metric | NNVC | IPWR |
|---|---|---|
| Price | $1.43 | $2.27 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 157.6K | 132.2K |
| Earning Date | 11-24-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.92 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $2,550.55 |
| Revenue Next Year | N/A | $600.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.85 | $1.90 |
| 52 Week High | $1.93 | $9.30 |
| Indicator | NNVC | IPWR |
|---|---|---|
| Relative Strength Index (RSI) | 53.39 | 32.25 |
| Support Level | $1.23 | N/A |
| Resistance Level | $1.49 | $3.33 |
| Average True Range (ATR) | 0.10 | 0.27 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 59.26 | 34.69 |
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company is engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific antiviral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing. The Company's platform is based on host-mimicry and thereby has uniquely enabled the development of broad-spectrum antiviral drugs that the viruses would be unable to escape, a critical unmet need in antiviral therapeutics.
Ideal Power Inc is engaged in the development of its broadly patented bidirectional power switches, creating efficient and ecofriendly energy control solutions for electric vehicles, electric vehicle charging, renewable energy, energy storage, UPS / data center, solid-state circuit breaker and other industrial and military applications. The company is focused on its patented Bidirectional, Bipolar Junction Transistor (B-TRAN) semiconductor technology. B-TRAN is a double-sided bidirectional AC switchable to deliver substantial performance improvements over conventional power semiconductors. The primary raw material used in the fabrication of B-TRAN devices is silicon wafers.